We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 86,650

Medical Board of Australia v Hung Phan
  • MinterEllison
  • Australia
  • October 18 2018

A former medical practitioner, Dr Hung Phan engaged in professional misconduct after making 13,465 fraudulent Medicare claims totalling $834,188.20.


Transferring marketing authorizations as a result of Brexit: key tax considerations
  • Baker McKenzie
  • United Kingdom, European Union
  • October 18 2018

Developing, producing and marketing medicinal products involves a significant amount of regulation grounded in EU law for pharmaceutical companies to


Brexit no-deal technical notices - implications for the life sciences sector
  • Penningtons Manches LLP
  • United Kingdom, European Union
  • October 18 2018

On 23 August 2018, the UK Government published the first tranche of a series of technical notices providing guidance for businesses on how to prepare


Inquest into the death of Stephen Robert Atkins
  • MinterEllison
  • Australia
  • October 18 2018

Stephen Robert Atkins presented at the Emergency Department of the Flinders Medical Centre (FMC) with a 7 day history of Horner's


New Law Requires Disclosure of Biologic Patent Settlement Agreements to Antitrust Authorities
  • Jones Day
  • USA
  • October 17 2018

Last week, the Patient Right to Know Drug Prices Act ("Act") became law. The Act requires pharmaceutical companies to disclose to antitrust agencies


Preparing for Ohio’s Cybersecurity Safe Harbor Law
  • Thompson Hine LLP
  • USA, Global
  • October 17 2018

Cyberattacks are a reality that can impact even the best-prepared business. Unfortunately, corporate victims of data breaches often become the targets


Slovakia and Czechia: State re-export bans on medicines
  • Abraham & Partneri
  • Slovakia, Czech Republic
  • October 17 2018

As of 1 January 2017, only marketing authorization holder (MAH) of a medicinal product or a distributor with a prior written consent from such MAH can


FDA Sued for Failure to Implement “High-Risk” FSMA Provisions by the Statutory Deadlines
  • Keller and Heckman LLP
  • USA
  • October 17 2018

The Center for Food Safety (CFS) and the Center for Environmental Health (CEH) filed suit against the FDA on October 15 for failure to implement


Pharmaceutical Company Agrees to $625 Million False Claims Act Settlement
  • Jones Day
  • USA
  • October 17 2018

The civil settlement is one the largest FCA settlements in recent years. The Department of Justice ("DOJ") recently announced that it agreed with


Updated Tools for Your HIPAA Toolkit: Security Risk Assessment
  • Spencer Fane LLP
  • USA
  • October 17 2018

In the wake of the record setting $16 Million dollar settlement and resolution agreement with Anthem, Inc, the Office for Civil Rights (OCR) and